Ochre Bio CEO Jack O’Meara steps down, out­lines plans for next start­up

8 months ago
People
Startups

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

8 months ago
People
Cell/Gene Tx

Im­mat­ics los­es Bris­tol My­er­s' sup­port on Phase 1 bis­pe­cif­ic T cell en­gager

8 months ago
Deals
R&D

Phys­i­cal ther­a­py start­up Sword Health shifts to a nov­el way of get­ting paid

8 months ago
Health Tech

Mer­ck­'s Eli­av Barr on sub­cu­ta­neous Keytru­da, Sum­mit and deal shop­ping

8 months ago
People
R&D

Ex­elix­is’ drug staves off neu­roen­docrine tu­mor pro­gres­sion in broad swath of pa­tients

8 months ago
R&D

Biotech IPO mar­ket still in flux fol­low­ing flashy Fri­day triple­head­er

8 months ago
Financing
Startups

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

8 months ago
R&D
Pharma

Keytru­da and Lenvi­ma still have an­oth­er hill to climb fol­low­ing lat­est da­ta drop

8 months ago
R&D
Pharma

As­traZeneca un­veils what it calls ‘prac­tice-chang­ing’ Imfinzi da­ta in blad­der can­cer

8 months ago
R&D
Pharma

Scor­pi­on de­tails ear­ly da­ta on tar­get­ed breast can­cer drug as it seeks to chal­lenge No­var­tis, Roche

8 months ago
R&D

In­cyte gears up to face FDA once again with more Zynyz da­ta in rare anal can­cer

8 months ago
R&D
Pharma

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

8 months ago
R&D

Up­dat­ed: Bris­tol My­ers touts LAG-3 strat­e­gy in lung can­cer, but da­ta caveats damp­en ex­cite­ment

8 months ago
R&D

House pass­es Biose­cure Act; Mod­er­na out­lines more cost cuts; What's hap­pen­ing at #ES­MO24; and more

8 months ago
Weekly

Nu­va­tion Bio to head to FDA with pooled ROS1-pos­i­tive lung can­cer da­ta

8 months ago
R&D

Up­dat­ed: GSK, iTeos re­ju­ve­nate strug­gling TIG­IT space with pos­i­tive Phase 2 Jem­per­li com­bo da­ta in lung can­cer

8 months ago
R&D
Pharma

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

8 months ago
Deals
Law

Ad­comm says In­ter­cep­t's rare liv­er dis­ease drug should not get full ap­proval

8 months ago
Pharma
FDA+

Ar­bor Biotech­nolo­gies cuts ear­ly-stage dis­cov­ery work, lays off staff

8 months ago
People
R&D

Af­ter a huge IPO and ac­qui­si­tion, Zymer­gen caps off bank­rupt­cy with $30M SEC penal­ty

8 months ago
Law

Post-Hoc: Big promis­es built Mod­er­na. They might al­so be its un­do­ing

8 months ago
Editor's note

Atea's poly­merase in­hibitor fails in late-stage Covid-19 treat­ment tri­al

8 months ago
R&D
Coronavirus

Au­rinia re­struc­tures board, bring­ing in Kevin Tang and keep­ing CEO

8 months ago
People
First page Previous page 104105106107108109110 Next page Last page
A service from the Financial Times